Shield Therapeutics, Vast Resources and Alan Green on 3 Stocks

Justin Waite
Justin Waite
Vox Markets Podcast with Justin Waite
13:53, 1st March 2021

AudioBoom Player

DYOR Disclaimer

If you find this podcast useful please give it a rating and review on iTunes by clicking here

On today's Vox Markets Podcast: Shield Therapeutics, Vast Resources and Alan Green on 3 Stocks

Tim Watts Chief Executive Officer of Shield Therapeutics #STX FOLLOW talks about their recent £25m fundraise and what the funds will be used for.

Shield is a commercial stage, pharmaceutical company with a focus on addressing iron deficiency with its lead product Feraccru ® /Accrufer ® (ferric maltol) ®, a novel, stable, non-salt based oral therapy for adults with iron deficiency with or without anaemia. Shield is quoted on AIM (STX).

Andrew Hall, Chief Commercial Officer of Vast Resources #VAST FOLLOW & Marcus Brewster the new General Manager of its Baita Plai Polymetallic Mine in Romania talks about operations and the revised mining plan.

Vast Resources plc is a United Kingdom AIM listed mining company with mines and projects in Romania and Zimbabwe. In Romania, the Company is focused on the rapid advancement of high-quality projects by recommencing production at previously producing mines.

(Interview starts at 8 minutes 39 seconds)

Alan Green CEO of Brand Communications talks about:


Bacanora Minerals #BCN FOLLOW

Lexington Gold #LEX FOLLOW

(Interview starts at 20 minutes 6 seconds)

Disclaimer & Declaration of Interest

The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.

Login or register to post comments

Recent Articles